Literature DB >> 8283141

Activation of NF-kappa B may be necessary but is not sufficient for induction of H-2 antigens by TNF in J558L murine myeloma cells.

J D Wolchok1, A R Goodman, J Vilcek.   

Abstract

We have investigated the role of the transcription factor NF-kappa B in the induction of H-2 antigens by tumor necrosis factor (TNF) in murine J558L myeloma cells. An earlier report suggested that J558L cells may have a defect in NF-kappa B activation in response to some stimuli. Treatment of J558L cells with either TNF or lipopolysaccharide (LPS) resulted in nuclear translocation of NF-kappa B, as demonstrated by electrophoretic mobility shift assay. Both TNF and LPS activated the same NF-kappa B nuclear complexes, composed of the p50 and p65 subunits. LPS mediated a stronger and more sustained activation of NF-kappa B than TNF. In contrast, TNF induced higher levels of H-2 antigen surface expression than did LPS, suggesting that activation of NF-kappa B is not sufficient for optimal enhancement of H-2 expression. An inhibitor of NF-kappa B activation, pyrrolidinedithiocarbamate (PDTC), dramatically reduced the induction of H-2 antigen by TNF, supporting the view that NF-kappa B is required for TNF-induced H-2 antigen expression. Constitutive levels of H-2 antigen expression on the cell surface and of nuclear NF-kappa B also decreased after PDTC treatment. However, PDTC had a smaller inhibitory effect on LPS-induced NF-kappa B activation and H-2 antigen expression, suggesting that TNF and LPS activate NF-kappa B by somewhat different pathways.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8283141     DOI: 10.1002/jlb.55.1.7

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  1 in total

1.  Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

Authors:  Elliott J Brea; Claire Y Oh; Eusebio Manchado; Sadna Budhu; Ron S Gejman; George Mo; Patrizia Mondello; James E Han; Casey A Jarvis; David Ulmert; Qing Xiang; Aaron Y Chang; Ralph J Garippa; Taha Merghoub; Jedd D Wolchok; Neal Rosen; Scott W Lowe; David A Scheinberg
Journal:  Cancer Immunol Res       Date:  2016-09-28       Impact factor: 11.151

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.